Guatemala
Tuberculosis profile
| High HIV burden |
Population  2012 15 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.31 (0.28–0.34) 2.1 (1.9–2.2)
Mortality (HIV+TB only) 0.71 (0.61–0.82) 4.7 (4.1–5.5)
Prevalence  (includes HIV+TB) 17 (8.2–28) 110 (54–187)
Incidence  (includes HIV+TB) 9.1 (7.5–11) 60 (50–72)
Incidence (HIV+TB only) 1.5 (1.2–1.8) 10 (8.2–12)
Case detection, all forms (%) 38 (32–46)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 2 212 (67) Relapse 144 (72)
Smear-negative 382 (12) Treatment after failure 18 (9)
Smear-unknown / not done 0 (0) Treatment after default 39 (19)
Extrapulmonary 311 (9) Other 0 (0)
Other 393 (12)      
Total new 3 298   Total retreatment 201  
           
Other (history unknown)          
Total new and relapse 3 442   Total cases notified 3 499  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio      
Age < 15      
Laboratories 2012
Smear (per 100 000 population) 1.9
Culture (per 5 million population) 3.3
Drug susceptibility testing (per 5 million population) 1.0
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 86   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 82  
Retreatment 64  
TB/HIV 2012 Number (%)
TB patients with known HIV status 2 982 (85)
HIV-positive TB patients 293 (10)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 278 (95)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 3 (1.8–4.6) 26 (20–34)
MDR-TB cases among notified pulmonary
TB cases
89 (55–140) 53 (40–69)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 37 (1%) 74 (37%) 261
Laboratory-confirmed MDR-TB cases 7 17 69
Patients started on MDR-TB treatment     39
Financing TB control 2013
National TB programme budget (US$ millions) <1
% Funded domestically 76%
% Funded internationally 14%
% Unfunded 10%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-25 Data: www.who.int/tb/data